A Randomized, Double-Masked, Multicenter, Laser-Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-Therapy in Patients With Visual Impairment Due to Diabetic Macular Edema

Trial Profile

A Randomized, Double-Masked, Multicenter, Laser-Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-Therapy in Patients With Visual Impairment Due to Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESTORE; RESTORE-Ext
  • Sponsors Novartis
  • Most Recent Events

    • 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 08 May 2013 Data were presented at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting, according to a Novartis media release.
    • 05 Oct 2012 Extension study interim analysis presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top